摘要
利妥昔单抗(rituximab, RTX)是一种针对表达于B淋巴细胞的CD20的人/鼠嵌合单克隆抗体,最初用于治疗淋巴瘤,但越来越多地用于治疗自身免疫性疾病。膜性肾病(membranous nephropathy, MN)是成人肾病综合征的常见病因,在大多数患者中,磷脂酶A2受体(phospholipase A2 receptor, PLA2R)作为靶抗原的鉴定显著改变了MN的治疗,并为B细胞耗竭剂(如RTX)提供了基本原理。RTX现在被认为是MN的一线治疗选择,特别是对于肾功能恶化的中度和高度风险的患者。其治疗特发性膜性肾病(idiopathic membranous nephropathy, IMN)的经验已近20年。在这篇综述中,我们概述了目前的文献中RTX治疗特发性膜性肾病的相关研究进展。
Rituximab (RTX) is a human/mouse chimeric monoclonal antibody targeting CD20 expressed on B lymphocytes. It was initially used to treat lymphoma, but increasingly used to treat autoimmune diseases. Membrane nephropathy (membranous nephropathy, MN) is a common cause of adult ne-phrotic syndrome. In most patients, the identification of phospholipase A2 receptor (PLA2R) as a target antigen has significantly changed the treatment of MN and provided a basic rationale for B cell depletion agents (such as RTX). RTX is now considered as a first-line treatment option for MN, especially for patients with moderate and high risk of renal function deterioration. Its experience in treating idiopathic membranous nephropathy (IMN) has been nearly 20 years. In this review, we reviewed the current literature on RTX in the treatment of idiopathic membranous nephropathy.
出处
《临床医学进展》
2023年第2期1517-1529,共13页
Advances in Clinical Medicine
